|
| 37940446 | Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. | Eur Urol Oncol | 2024 |
| 36216760 | The development of an electronic geriatric assessment tool: Comprehensive health assessment for my plan (CHAMP). | J Geriatr Oncol | 2023 |
| 37782296 | 2023 American Society of Clinical Oncology (ASCO) Symposium: Meeting highlights. | Can Urol Assoc J | 2023 |
| 37685670 | Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer. | J Clin Med | 2023 |
| 37761908 | Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning. | Genes (Basel) | 2023 |
| 37459767 | Implementing geriatric assessment and management for older Canadians with cancer: Adherence to and satisfaction with the intervention, results of the 5C study. | J Geriatr Oncol | 2023 |
| 36950912 | Editorial Comment. | J Urol | 2023 |
| 37421787 | Daily physical activity monitoring in older adults with metastatic prostate cancer on active treatment: Feasibility and associations with toxicity. | J Geriatr Oncol | 2023 |
| 36988104 | Symptom experiences of older adults during treatment for metastatic prostate cancer: A qualitative investigation. | J Geriatr Oncol | 2023 |
| 36988103 | Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer. | J Geriatr Oncol | 2023 |
| 37262068 | The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer. | PLoS One | 2023 |
| 36917921 | Feasibility and acceptability of remote symptom monitoring (RSM) in older adults during treatment for metastatic prostate cancer. | J Geriatr Oncol | 2023 |
| 36849325 | Sarcopenia in Men With Bone-Predominant Metastatic Castration-Resistant Prostate Cancer Undergoing Ra-223 Therapy. | Clin Genitourin Cancer | 2023 |
| 36473126 | Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial. | J Clin Oncol | 2023 |
| 36682218 | The role of frailty in modifying physical function and quality of life over time in older men with metastatic castration-resistant prostate cancer. | J Geriatr Oncol | 2023 |
| 36795891 | Rucaparib or Physician's Choice in Metastatic Prostate Cancer. | N Engl J Med | 2023 |
| 36371403 | Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis. | Clin Genitourin Cancer | 2023 |
| 34672942 | A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer. | Can Urol Assoc J | 2022 |
| 35343467 | Spine Stereotactic Body Radiotherapy for Prostate Cancer Metastases and the Impact of Hormone Sensitivity Status on Local Control. | Neurosurgery | 2022 |
| 35397952 | Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. | Eur Urol | 2022 |
| 35628909 | Metronomic Chemotherapy for Advanced Prostate Cancer: A Literature Review. | J Clin Med | 2022 |
| 36272847 | UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer. | Urol Oncol | 2022 |
| 36351725 | Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. | BMJ Open | 2022 |
| 35887929 | Prostate Cancer Brain Metastasis: Review of a Rare Complication with Limited Treatment Options and Poor Prognosis. | J Clin Med | 2022 |
| 34026638 | Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer. | Front Oncol | 2021 |
| 33705221 | Editorial Comment. | J Urol | 2021 |
| 33608426 | Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. | J Nucl Med | 2021 |
| 33798267 | Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen-receptor-targeted therapy for metastatic castration-resistant prostate cancer. | Cancer | 2021 |
| 34213559 | Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer. | JAMA Netw Open | 2021 |
| 32374715 | A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. | Can Urol Assoc J | 2020 |
| 32520699 | Bone scan use in the management of metastatic castration-resistant prostate cancer: Survey of practice patterns among Canadian radiation oncologists, medical oncologists, and urologists. | Can Urol Assoc J | 2020 |
| 30642810 | What Is Oligometastatic Prostate Cancer? | Eur Urol Focus | 2019 |
| 31802949 | Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome. | Cancer Manag Res | 2019 |
| 31073853 | Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone. | Support Care Cancer | 2019 |
| 31079079 | Clinical and Cost-effectiveness of a Comprehensive geriatric assessment and management for Canadian elders with Cancer-the 5C study: a study protocol for a randomised controlled phase III trial. | BMJ Open | 2019 |
| 29191639 | Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. | Urology | 2018 |
| 28056464 | Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. | Br J Cancer | 2017 |
| 28259819 | Resistance to metronomic chemotherapy and ways to overcome it. | Cancer Lett | 2017 |
| 28169118 | Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline. | Clin Oncol (R Coll Radiol) | 2017 |
| 28785760 | Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. | Ann Intern Med | 2017 |
| 27081582 | Avascular Necrosis of the Femoral Head After Palliative Radiotherapy in Metastatic Prostate Cancer: Absence of a Dose Threshold? | Cureus | 2016 |
| 27651308 | Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. | Cancer Res | 2016 |
| 27561266 | High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. | Eur J Clin Pharmacol | 2016 |
| 27335772 | Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). | J Bone Oncol | 2016 |
| 26799652 | Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). | Autophagy | 2016 |
| 27008982 | Disease volume and distribution as drivers of treatment decisions in metastatic prostate cancer: From chemohormonal therapy to stereotactic ablative radiotherapy of oligometastases. | Urol Oncol | 2016 |
| 25683285 | Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. | Prostate | 2015 |
| 26542984 | Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. | Oncologist | 2015 |
| 25971294 | Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy. | Ann Palliat Med | 2015 |
| 23728939 | Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. | Invest New Drugs | 2014 |